In part 2 of our Q&A, Okamura addresses the need for biopharma companies to leverage digital technologies in disease management. The post Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business appeared first on MedCity News.

Scott Davis is the CEO of Ekso Bionics, an innovative medical device company making wearable exoskeletons for use in construction but perhaps, more importantly, to help people contending with spinal cord injury. The post MedCity Pivot: A Conversation About Wearable Robots with Scott Davis appeared first on MedCity News.

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

The next wave of Medtech innovation must deliver truly smart connected care—not only building on our progress in collecting and integrating information about a patient, such as vital signs, diagnostic results and health history—but also using software to prioritize this information, streamline care delivery and provide actionable insights.

The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests.

Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.